Replies to post #244068 on Biotech Values

[DewDiligence]

ONCS -50% on failure of TAVO-EP+Keytruda in single-arm_phase-2_trial:

https://www.prnewswire.com/news-releases/oncosec-announces-clinical-data-of-the-keynote-695-trial-assessing-tavo-ep-in-combination-with-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-refractory-to-anti-pd-1-treatment-301787777.html

The last patient started treatment in December 2020; clinical database lock occurred in October 2022.

The primary endpoint of overall response rate (ORR) per RECIST v1.1 assessed by blinded independent central review (BICR) was not met.

Inasmuch as ONCS had a restructuring and 45% layoff in Oct 2022 (#msg-170117130)—just as the database for this trial was locked—you would think investors would’ve taken that as a “tell.”